BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Antitope Announces Protein Deimmunisation Research Agreement With Research Corporation Technologies


4/23/2013 11:29:59 AM

Cambridge, UK, 22nd April 2012 - Antitope Ltd, UK ("Antitope") today announced a Research Agreement with Research Corporation Technologies Inc., USA ("RCT") to re-engineer a toxic protein warhead for the next generation of antibody drug conjugates (ADCs) using it's proprietary Composite Protein technology. The resulting "deimmunised" protein is expected to have a range of therapeutic applications especially in the treatment of cancers. Under the Agreement, Antitope will be eligible for research fees and subsequent milestone and royalty payments.

"We are delighted to have been chosen by RCT for this exciting collaboration to produce a novel therapeutic protein with a broad range of clinical applications." said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. "This collaboration, using Antitope's expertise in protein engineering and immunogenicity technologies, will assist RCT in progressing the new molecule to the clinical stage."

"We are pleased to be working with Antitope to deimmunise our protein warhead using their proven technology platform. RCT plans to partner the new warhead with companies interested in developing novel ADC products to treat cancer and other diseases" said Dr Kurt R Gehlsen, Chief Scientific Offier of RCT.

About Antitope

Antitope Ltd., is a privately-held Cambridge, UK based biotechnology company specialising in immunogenicity testing abd the engineering of therapeutic antibodies and proteins with reduced immunogenicty. Antitope's proprietary EpiScreen technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Th eproprietary Compsoite Human Antibody and Compsoite Protein technology result in the generation of fully humanised antibodies and therapeutic proteins devoid of T cell epitopes. Antitope's proprietary Composite CHO technology results in the generation of high yielding manufacturing cell lines suitable for the direct transfer to GMP manufacturing. Antitope has established multiple commercial relationships withleading biotechnology and pharmaceutical companies worldwide.

For more information, please visit www.antitope.co.uk or contact Dr Neil Butt, Business Development Director, info@antitope.co.uk

About Research Technology Corporation, Inc.

RCT is a Tucson, Arizona-based technology investment and management company that provides early-stage funding and development from promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT's technology portfolio includes platforms that support the discovery, development and manufacturing of therapeutics. Current platform technologies include Pichia and E. coli expression systems and novel binding scaffolds.

To learn more about RCT and our business, visit www.rct.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->